Targeted HIFU in the treatment of index lesions in localized prostate cancer

A new review article offers us some greater clarity related to the role of targeted, high-intensity focused ultrasound (HIFU) to treat carefully selected areas of the prostate to eliminate primary or index lesions while leaving the remainder of the prostate intact. … READ MORE …

Patient choice and the effectiveness and safety of HIFU

An interesting article has just been published in the Journal of Urology which helps to provide information (and context) about the quality of data supporting the use of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer. … READ MORE …

Major US insurer to cover use of HIFU for treatment of radiorecurrent prostate cancer

According to a media release issued on March 18 by EDAP TMS, the US healthcare insurance firm CIGNA has agreed to cover the use of high-intensity focal ultrasound (HIFU) as a second-line, salvage therapy for men with radiorecurrent prostate cancer. … READ MORE …

The misleading promotion of HIFU as a treatment for prostate cancer

We were recently made aware of a video on Facebook promoting high-intensity focused ultrasound (HIFU) as a treatment for prostate cancer. The video promotes the services of a particular group of physicians who specialize in this form of treatment. They are, of course, entirely entitled to do this. READ MORE …

Practical aspects of deciding whether HIFU is an appropriate treatment “for you”

An article by Julie Appleby of Kaiser Health News, posted yesterday on the STAT health news web site, asks whether high-intensity focused ultrasound (HIFU) is being “over-sold” to prostate cancer patients based on the limited outcome data currently available. … READ MORE …

Salvage HIFU in men with a rising PSA after first-line surgery

We have long presumed that it would be possible to consider high-intensity focused ultrasound (HIFU) as a form of salvage therapy for men with biochemically recurrent disease after either surgery or radiation therapy. Now there are some data on this concept. … READ MORE …

Let’s call this “new technology” what it is; it’s a form of HIFU

According to information in the Boston Herald earlier today, researchers at Brigham & Women’s Hospital in Boston (one of the main teaching hospitals associated with Harvard University) are testing a new form of technology to treat localized prostate cancer. … READ MORE …

5-year outcomes from a large cohort of HIFU-treated patients in the UK

For several years now, the Ahmed/Emberton-led research team in the United Kingdom (UK) has published the majority of the detailed outcomes data from treatment of men with localized prostate cancer using high-intensity focused ultrasound (HIFU). This group has now given us 5-year outcomes on a cohort of > 550 patients. … READ MORE …

Data from a prospective trial of HIFU-based hemiablation for localized prostate cancer

A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium. … READ MORE …

FDA approves EDAP TMS’s Ablatherm technology for HIFU therapy

As predicted, the U.S. Food and Drug Administration apparently approved the Ablatherm brand of equipment for high-intensity focused ultrasound (HIFU) on November 9 for “the ablation of prostate tissue.” … READ MORE …

Focal HIFU is “sexual function sparing” in a cohort of 118 selected patients

A new paper in European Urology has suggested that men with localized prostate cancer who are treated by focal forms of high-intensity focused ultrasound (HIFU) have “a return to baseline International Index of Erectile Function — erectile and total International Index of Erectile Function scores” by 6 months after treatment which was maintained at 1 year. … READ MORE …

CureTalk about HIFU for prostate cancer now available on line

Your sitemaster is pleased to be able to report a forthright and interesting discussion yesterday with Dr. Stephen Scionti about the current and future potential of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer. … READ MORE …

Our next prostate cancer CureTalk — with Dr. Stephen Scionti about the role of HIFU

Dr. Stephen Scionti is almost certainly the most experienced practitioner of high-intensity focused ultrasound (HIFU) as a first-line treatment for prostate cancer practicing in the USA today — although he has had to actually treat the vast majority of his patients outside of the USA. … READ MORE …

EDAP TMS submits revised application for approval of their form of HIFU technology

As predicted in yesterday’s post about the nature of the approval of SonaCare Medical’s Sonablate technology as a “generic” form of treatment for prostate tissue ablation, we are likely to see rapid approval of the Ablatherm brand of HIFU technology here in America very soon as well. … READ MORE …

FDA approves HIFU for “prostate tissue ablation”

According to a media release issued by SonaCare Medical early this morning, the company has received approval from the U.S. Food and Drug Administration (FDA) to market its Sonablate® 450 technology in the U.S.A. for prostate tissue ablation. … READ MORE …